Navigation Links
GeneAmp PCR Carry-over Prevention Kit from Applied Biosystems

ProductsGeneAmp PCR Carry-over Prevention Kit from Applied Biosystems
Company Applied Biosystems
Item GeneAmp PCR Carry-over Prevention Kit
Price $150.00
Description Enzymatic method stops PCR carry-over contamination, which prevents false positive results Designed to degrade PCR products from previous PCR amplifications without degrading native nucleic acid templates, which improves amplification Optimized for use with GeneAmp PCR core reagents and GeneAmp instrument systems

The GeneAmp PCR Carry-over Prevention Kit provides reagents for a simple yet powerful method of ensuring that PCR products cannot be reamplified in subsequent PCR amplifications, thereby preventing false positive results. This kit uses an enzymatic reaction analogous to the restriction-modification and excision-repair systems of cells to specifically degrade PCR products from previous PCR amplifications in which dUTP has been incorporated, without degrading native nucleic acid templates.

The method used to render PCR products susceptible to degradation involves substituting dUTP for dTTP in the PCR mixture, and pretreating all subsequent PCR mixtures with the enzyme, AmpErase Uracil N-glycosylase (UNG) prior to PCR amplification.1 Products from PCR amplification contain uracil, and are readily distinguishable from native thymidine-containing DNA templates. Products from previous PCR amplifications are eliminated by excising uracil residues using UNG, and degrading the resulting abasic polynucleotide with heat. Although UNG is active on single- and double-stranded dU-containing DNA,2 ribouracil residues in RNA and dUTP itself are not substrates for UNG.3

AmpliTaq and AmpliTaq Gold DNA polymerase, and the other components of the PCR reaction mixture remain intact during UNG treatment, providing PCR amplification free of PCR product carry-over. The dU-containing PCR product behaves like dT-containing DNA in blotting, cloning, sequencing, and most other post-PCR analyses.4

1. Longo, M.C., et al. 1990. Gene 93:125-128
2. Varshney, U., et al. 1988. J. Biol. Chem.263:7,776-7,784.
3. Lindahl, T., et al. 1977. J. Biol. Chem.252:3,286-3,294.
4. Erlich, H.A. et al. 1991. Science 252: 1,643-1,651. For Research Use Only. Not for use in diagnostic procedures.

Info Applied BiosystemsApplied Biosystems
850 Lincoln Centre Drive
Foster City, CA 94404

Call Applied Biosystems to buy products (US and Canada only; other locations use numbers below)
USA Canada 1-650-425-3266
Customer Service: 650-638-5800
Fax Number: 650-638-5884
Web Site: http://home.appliedbiosystems.com/
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. GeneAmp AccuRT RNA PCR Kit with Controls from Applied Biosystems
2. GeneAmp PCR System 2700 from Applied Biosystems
3. Gold-plated 96-Well GeneAmp PCR System 9700 from Applied Biosystems
4. GeneAmp High Fidelity PCR from Applied Biosystems
5. GeneAmplimer HIV-1 Control Reagents from Applied Biosystems
6. ProteinPilot Software from Applied Biosystems
7. Applied Biosystems 2720 Thermal Cycler from Applied Biosystems
8. 4000 Q TRAP LC/MS/MS System from Applied Biosystems
9. Genome Sequencer 20 System from Roche Applied Science
10. RTS AviTag E. coli Biotinylation Kit, Plasmid; Cloning vector and in vitro protein mono-biotinylation system for use with RTS 100 and RTS 500 E. coli HY Kits from Roche Applied Science
11. RTS AviTag E. coli Biotinylation Kit, Linear Template; Linear template generation and in vitro protein mono-biotinylation system for use with RTS 100 expression reactions from Roche Applied Science
Immobilized E. coli Lysate from Pierce Biotechnology, Inc.
EcoR I/Hind III End Modification Kit from Novagen
...gen and antibody-based immunoaffinity matrices, su...times without compromising antigen-antibody reacti...ts has precluded the application of these methods ...stern Blot Mild Antibody Stripping Solution contai...
ReBlot™ Western Blot Recycling Kit from Upstate
Biology Products:
(Date:11/20/2009)...vember 19, 2009 The estimated 4.6 million America...of developing respiratory symptoms due to poor air...ire study undertaken earlier this year by investig...erinary Medicine. , The studywhich polled more t... percent of individuals working in barns complaine...
(Date:11/20/2009)... production of flax shives, and generated from Br...to those which engulf fields in spring, can be use...y two studies carried out by Spanish and Dutch res...nd Sustainable Energy Reviews . , "These studies ... production of bioethanol from two, as yet unexplo...
(Date:11/19/2009)...years ago, at the end of the last ice age, North A...ng such iconic creatures as mammoths, mastodons, c...gan their precipitous slide to extinction. , And...hose diversity of large animals equaled or surpass... now, an entirely novel ecosystem emerged as broad...
Breaking Biology News(10 mins):Barn personnel experience higher-than-average rates of respiratory symptoms 2Flax and yellow flowers can produce bioethanol 2After mastodons and mammoths, a transformed landscape 2After mastodons and mammoths, a transformed landscape 3Can the relationship between doctors and drug companies ever be a healthy one 3F 52168 1Can the relationship between doctors and drug companies ever be a healthy one 3F 52168 2Laser technology creates new forms of metal and enhances aircraft performance 13107 1Laser technology creates new forms of metal and enhances aircraft performance 13107 2NYU physicists find way to explore microscopic systems through holographic video 13103 1NYU physicists find way to explore microscopic systems through holographic video 13103 2NYU physicists find way to explore microscopic systems through holographic video 13103 3
...ent of Civil and Environmental Engineering suggest...y a major role in the health of large areas of oce...n the Dec. 25 issue of the Journal of Fluid Mechan...und aquatic plants and demonstrates the importance...his new understanding can be used to guide restora...
... Prostate Cancer Foundation, largely through the g...o four institutions, including Weill Cornell Medic...cancer. The gift is one of the largest-ever indivi...e multidisciplinary research team, created by the ... novel nanomedicine for prostate cancer that can b...
...ement and Budget evaluates R&D programs at the U.S...es using a questionnaire that asks about many aspe...OMB rates programs based on the answers, and an "i...uences for a program or agency. After having trou...nstrate efficiency, EPA asked the National Researc...
Other Biology News:River plants may play major role in health of ocean coastal waters 2Nanomedicine research for prostate cancer supported by $5 million gift 2Nanomedicine research for prostate cancer supported by $5 million gift 3
(Date:11/20/2009)...Spain and Latin American countries have an opportu...ectors. Researchers from the University of Valenci...on, have studied the productive fabric of the Span...at Spain,s food and plant sectors have more clout ...echnology as applied to food and plants has been o...
(Date:11/20/2009)..., , SEATTLE, Nov. 20 /PRNewswire-FirstCal...A: CTIC) announced today that the Ninth Circuit Co...r and ruled that CTI should be allowed to pursue a...he case back to the District Court for trial. CTI...ormer third-party reimbursement consultant for CTI...
(Date:11/19/2009)..., , SEATTLE, Nov. 19 /PRNewswire-FirstCall/ -...ced unaudited financial results for the third quar... ended September 30, 2009, Omeros reported a net l...ed to a net loss of $7.4 million, or $2.54 per sha...hs ended September 30, 2009, the Company reported ...
(Date:11/19/2009)..., , MALVERN, Pa. and WALTHAM, Mass., Nov....MR) and Decision Resources find that the leading d...nia in Europe is broad-spectrum activity against g...he variety of organisms that can cause nosocomial ...t they look primarily for agents that provide appr...
Breaking Biology Technology:Spanish biotechnology should focus on food and plant sectors to be more competitive 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3